1. EachPod

Oncology Times - OncTimes Talk - Podcast

Oncology Times - OncTimes Talk

 Oncology Times

OncTimes Talk features a variety of podcast series ranging from breaking news and oncology conference coverage to story round-ups and in-depth interviews with current experts and leaders in oncology.

News Medicine Science & Medicine Health
Update frequency
every 4 days
Average duration
13 minutes
Episodes
199
Years Active
2009 - 2025
Share to:
The Thinking Behind ASCO’s Top Five List

The Thinking Behind ASCO’s Top Five List

00:09:37  |   Wed 03 Jul 2013
How Drug Shortages Affect Oncology

How Drug Shortages Affect Oncology

00:03:43  |   Mon 01 Jul 2013
Oncology Practices Expect Big Change

Oncology Practices Expect Big Change

00:07:59  |   Fri 01 Mar 2013
The Value of In-Person Meetings

The Value of In-Person Meetings

00:14:25  |   Fri 01 Mar 2013
Cancer’s Existential Impact on Survivors

Cancer’s Existential Impact on Survivors

00:03:07  |   Wed 23 Jan 2013
How Should Physicians Be Paid?

How Should Physicians Be Paid?

00:09:18  |   Mon 21 Jan 2013
Integrating Palliative & Standard Care

Integrating Palliative & Standard Care

00:23:03  |   Fri 16 Nov 2012
The Importance of “Competitive Mortality” in Oncology Care

The Importance of “Competitive Mortality” in Oncology Care

00:02:48  |   Fri 16 Nov 2012
Will CMS Cast Its Eye Toward Oncology?

Will CMS Cast Its Eye Toward Oncology?

00:08:52  |   Wed 12 Sep 2012
Final Rule for Medicare ACOs

Final Rule for Medicare ACOs

00:02:31  |   Wed 12 Sep 2012
Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

00:03:52  |   Thu 05 Aug 2010
From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)

From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)

00:08:12  |   Thu 17 Jun 2010
OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS

OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS

00:12:18  |   Fri 09 Apr 2010
OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD

OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD

00:08:39  |   Fri 09 Apr 2010
Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference

Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference

00:09:40  |   Fri 09 Apr 2010
Pregnancy & Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference

Pregnancy & Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference

00:16:07  |   Thu 01 Apr 2010
Program 4, Day 4, Monday Dec 8

Program 4, Day 4, Monday Dec 8

Prof Giuseppe Saglio of the University of Turin and San Luigi Gonzaga Hospital in Italy on nilotinib as a new standard of care for chronic myeloid leukaemia. ASH President Nancy Berliner of Brigham…
00:22:07  |   Wed 09 Dec 2009
Program 3, Monday Dec 7

Program 3, Monday Dec 7

George Canellos on aggressive chemotherapy's failure to benefit patients with high-risk B-cell lymphoma.... Massimo Martelli of University of Perugia on infused donor T-regulatory cells to prevent g…
00:23:20  |   Tue 08 Dec 2009
Program 1, First Day, Dec. 5

Program 1, First Day, Dec. 5

00:16:08  |   Mon 07 Dec 2009
Program 2, Sunday Dec. 6

Program 2, Sunday Dec. 6

George Canellos, What’s hot from the ASH Plenary Session.... Maria-Victoria Mateos of Salamanca University in Spain on melphalan as the better partner drug for bortezomib in multiple myeloma; Commen…
00:19:00  |   Mon 07 Dec 2009
Disclaimer: The podcast and artwork embedded on this page are the property of Oncology Times. This content is not affiliated with or endorsed by eachpod.com.